Machine learning is a field within artificial intelligence concerned with building systems that can recognize patterns in data and improve their performance on a task without being explicitly programmed with rules for every possible scenario. Rather than following a fixed set of if-then instructions written by a human programmer, a machine learning system is trained on data, and through that training process, develops its own internal model of the patterns relevant to the task at hand. In biopharma, machine learning has moved from a peripheral, experimental technology to an increasingly embedded part of drug discovery, clinical development, and manufacturing — making basic fluency in how it actually works a practical necessity rather than a specialized technical curiosity.
What Is the Difference Between Artificial Intelligence and Machine Learning?
Artificial intelligence is the broader field concerned with building systems capable of performing tasks that would typically require human intelligence — reasoning, problem-solving, pattern recognition, language understanding, and similar capabilities. Machine learning is a specific approach within that broader field, focused on systems that learn from data rather than relying on explicitly hand-coded rules. Not all artificial intelligence relies on machine learning — some earlier AI approaches used explicitly programmed rule-based logic — but the substantial majority of recent, high-profile AI progress, including the large language models and image recognition systems that have driven much of the recent public attention to AI, are built on machine learning techniques, and increasingly, a specific subset of machine learning called deep learning.
How Does Supervised Learning Differ From Unsupervised Learning?
Machine learning systems are commonly categorized by how they’re trained. In supervised learning, a system is trained using data that includes both the inputs and the correct, known outputs — for example, training a system to recognize cancerous cells in pathology images by showing it thousands of images that have already been labeled by human experts as cancerous or non-cancerous. The system learns to recognize the patterns that distinguish the labeled categories, and can then apply that learned pattern recognition to new, unlabeled data it hasn’t encountered before.
In unsupervised learning, the training data includes no predetermined correct answers — instead, the system is tasked with identifying patterns, groupings, or structures within the data on its own. This approach is often used for exploratory analysis, such as identifying previously unrecognized patient subpopulations within a large clinical dataset based on similarities the algorithm detects, without a researcher having specified in advance what those groupings should look like.
What Are Common Applications of Machine Learning and AI in Biopharma?
Machine learning has found application across nearly every stage of the biopharma value chain. In drug discovery, machine learning models can analyze vast chemical and biological datasets to identify promising drug candidates or predict how a candidate molecule is likely to behave, potentially narrowing an enormous field of possibilities to a more manageable set worth pursuing experimentally — a task that would be impractically slow using traditional, purely experimental screening approaches alone. In clinical development, machine learning supports patient recruitment and trial design by helping identify which patient populations are most likely to respond to a given therapy, and supports safety monitoring by helping detect adverse event patterns across large clinical datasets that might be difficult for human reviewers to identify manually.
In manufacturing, machine learning increasingly supports process analytical technology efforts, helping interpret the large volumes of real-time process data that modern bioprocessing monitoring generates, and in diagnostics, machine learning underlies an expanding category of tools that assist in image-based diagnosis, genomic data interpretation, and other pattern-recognition-heavy diagnostic tasks.
What Is Deep Learning, and Why Is It Discussed Separately From Machine Learning Generally?
Deep learning is a specific subset of machine learning built around artificial neural networks — computational structures loosely inspired by the layered structure of neurons in the brain, with multiple processing layers that allow the system to learn increasingly abstract representations of the input data as information passes through each successive layer. This layered, “deep” architecture is what gives the approach its name, and it’s part of why deep learning has proven particularly effective at tasks involving complex, high-dimensional data — image recognition, natural language processing, and genomic sequence analysis among them — where the relevant patterns are often too complex or subtle for simpler machine learning approaches to capture effectively.
The trade-off is that deep learning models typically require substantially more training data and computational resources than simpler machine learning approaches, and their internal reasoning tends to be considerably harder to interpret — a limitation discussed further below, and one that carries particular weight in regulated biopharma contexts where explainability is often not just a technical nicety but an actual regulatory expectation.
What Should Decision-Makers Understand About the Limitations of Machine Learning?
Despite its expanding application, machine learning carries real limitations worth understanding before evaluating any specific AI-driven product or claim. A machine learning system’s performance is fundamentally constrained by the quality and representativeness of the data it was trained on — a system trained primarily on data from one patient population may perform poorly, in ways that aren’t always obvious, when applied to a different population not well represented in its training data. Machine learning systems can also be genuinely difficult to interpret, particularly deep learning models, which can make accurate predictions without the underlying reasoning being easily explainable to a human reviewer — a meaningful concern in regulated clinical and diagnostic contexts where understanding why a system reached a particular conclusion can matter as much as the accuracy of the conclusion itself.
These limitations don’t undermine the genuine value machine learning has demonstrated across biopharma applications, but they do mean evaluating a machine learning-driven tool or claim requires more than confirming the underlying technology works in principle — it requires understanding the data it was trained on, how its performance has been validated, and whether its limitations have been adequately characterized for the specific context in which it’s being deployed.
MKA Insights